{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Borderline+Resectable+Pancreatic+Cancer", "query": { "condition": "Borderline Resectable Pancreatic Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 69, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Borderline+Resectable+Pancreatic+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T18:45:27.291Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02723331", "title": "Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Adenocarcinoma", "Pancreas Ductal Adenocarcinoma" ], "interventions": [ { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Academic Thoracic Oncology Medical Investigators Consortium", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 48, "start_date": "2016-12-30", "completion_date": "2022-12-28", "has_results": true, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-06-25T18:45:27.291Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Aurora, Colorado + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02723331" }, { "nct_id": "NCT04539808", "title": "NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8", "Stage I Pancreatic Cancer American Joint Committee on Cancer v8", "Stage III Pancreatic Cancer American Joint Committee on Cancer v8", "Stage IV Pancreatic Cancer American Joint Committee on Cancer v8" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Losartan Potassium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2021-05-27", "completion_date": "2027-01-05", "has_results": true, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-06-25T18:45:27.291Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04539808" }, { "nct_id": "NCT01903083", "title": "Chemoimmunotherapy and Radiation in Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Malignant Neoplasm" ], "interventions": [ { "name": "Tadalafil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Pancreaticoduodenectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-07", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2018-02-01", "last_synced_at": "2026-06-25T18:45:27.291Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01903083" }, { "nct_id": "NCT01821612", "title": "Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Acinar Cell Adenocarcinoma of the Pancreas", "Duct Cell Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage II Pancreatic Cancer", "Stage III Pancreatic Cancer" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "radiation", "type": "RADIATION" }, { "name": "surgery", "type": "PROCEDURE" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2013-05-29", "completion_date": "2018-06-15", "has_results": false, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-06-25T18:45:27.291Z", "location_count": 14, "location_summary": "La Jolla, California • Chicago, Illinois • Evanston, Illinois + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01821612" }, { "nct_id": "NCT02427841", "title": "Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Resectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Image Guided Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-01-21", "completion_date": "2022-12-12", "has_results": true, "last_update_posted_date": "2023-09-06", "last_synced_at": "2026-06-25T18:45:27.291Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02427841" }, { "nct_id": "NCT02305186", "title": "Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Neoadjuvant Chemoradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2015-03", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2021-08-13", "last_synced_at": "2026-06-25T18:45:27.291Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Hartford, Connecticut • Miami, Florida + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02305186" }, { "nct_id": "NCT01294358", "title": "Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Histologically or Cytologically Confirmed Pancreatic Ca", "Unresectable or Borderline Resectable Pancreatic Ca" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 7, "start_date": "2011-01-26", "completion_date": "2014-07-23", "has_results": true, "last_update_posted_date": "2019-11-13", "last_synced_at": "2026-06-25T18:45:27.291Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01294358" }, { "nct_id": "NCT01676259", "title": "A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "siG12D-LODER", "type": "DRUG" }, { "name": "Gemcitabine+nab-Paclitaxel", "type": "DRUG" }, { "name": "Folfirinox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Silenseed Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2018-03-07", "completion_date": "2023-08", "has_results": false, "last_update_posted_date": "2021-07-02", "last_synced_at": "2026-06-25T18:45:27.291Z", "location_count": 4, "location_summary": "Hackensack, New Jersey • New York, New York • Houston, Texas", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676259" }, { "nct_id": "NCT03099265", "title": "Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "neoadjuvant mFOLFIRINOX", "type": "DRUG" }, { "name": "Stereotactic body radiotherapy (SBRT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2017-06-26", "completion_date": "2019-09-18", "has_results": true, "last_update_posted_date": "2022-10-27", "last_synced_at": "2026-06-25T18:45:27.291Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03099265" }, { "nct_id": "NCT01836432", "title": "Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Carcinoma Non-resectable", "Locally Advanced Malignant Neoplasm" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Algenpantucel-L Immunotherapy", "type": "BIOLOGICAL" }, { "name": "5-FU Chemoradiation", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2013-05", "completion_date": "2017-03-24", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-06-25T18:45:27.291Z", "location_count": 32, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stamford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01836432" } ] }